Findings of a comparative retrospective analysis indicate that first-line octreotide long-acting release (LAR) and lanreotide treatment was associated with similar progression-free survival (PFS) and biochemical response in patients with metastatic, well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Head-to-head comparative data are lacking evaluating the outcomes between the 2 somatostatin analogs (SSAs) octreotide LAR and lanreotide, which are indicated as first-line therapy in well-differentiated, metastatic GEP-NETs. A single-institution, retrospective study compared octreotide LAR and lanreotide in terms of PFS and biochemical response in metastatic GEP-NETs. Results were presented at the 2020 North American Neuroendocrine Tumor Society Annual Symposium.
This study included all patients with metastatic, well-differentiated GEP-NETs who were treated with first-line octreotide LAR or lanreotide at University Hospitals Seidman Cancer Center. Kaplan-Meier methods were used to estimate the probability of PFS and between-group PFS difference. A multivariable logistic regression model was used to evaluate predictors of biochemical response.
A total of 131 patients with GEP-NETs who had received first-line SSAs were included in the analysis; of these, 105 patients were treated with octreotide LAR and 26 were treated with lanreotide. No statistical difference was seen in median PFS between the octreotide LAR–treated and lanreotide-treated cohorts (38.7 months vs 32.6 months; hazard ratio [HR], 1.1; 95% confidence interval [CI], 0.62-1.93; P = .75). Multivariable analysis showed no significant difference in PFS (HR, 1.04; 95% CI, 0.59-1.85; P = .89) after controlling for several variables, including age, gender, primary tumor type, liver tumor burden, and functionality. Also, no difference was observed in predictors of biochemical response, using both univariate (odds ratio [OR], 0.63; 95% CI, 0.17-2.29; P = .48) and multivariable analysis (OR, 0.25; 95% CI, 0.047-1.26; P = .09).
Findings of this retrospective analysis indicate that first-line octreotide LAR and lanreotide therapies were associated with similar PFS and biochemical response in patients with metastatic, well-differentiated GEP-NETs.
Source: Wu S, et al. North American Neuroendocrine Tumor Society 2020 Annual Symposium; October 1-3, 2020. Abstract C11.
